When recombinant OPG (OPG-Fc), a RANKL inhibitor like denosumab, was used for inhibition of RANKL in mice with a Brca1 mutation, the authors also observed reduced mammary tumor growth [23]. This evidence concerns the gene TNFRSF11B and breast cancer.